10.30.25 -- Will It Not Die? The BIOSECURE Act Back With Iterations

Antibody-drug conjugate (ADC) development requires tightly integrated manufacturing. Streamlined, end-to-end solutions reduce complexity, improve quality, and accelerate time-to-market.

Conducted alongside the Faculty of Medicine at Palacky University and supported by the Technology Agency of the Czech Republic, this project translated research into a viable medicinal product.

This session aims to equip viewers with practical knowledge to optimize their purification strategies, enhance product quality, and streamline manufacturing processes.

Lynn Cinelli, recent VP Global Biologics Supply Chain at Bristol Myers Squibb, provides her insights on selecting and managing external development and manufacturing partners.

Uncover how this expert approach to process transfer supports reliable, scalable commercial manufacturing in the rapidly growing biopharmaceutical market.

Vial fogging is a common phenomenon observed in lyophilized biologic drug products. This document presents two studies that explore factors contributing to fogging and inform selection decisions.

Explore the ways to design and de-risk molecules, streamlining the path to GMP manufacturing and clinical trials, and case studies that provide insight into key activities.

Leveraging deep expertise in biologics development, AbZelectPRO™ streamlines the IND application pathway, ensuring smooth progression into clinical phases.

Strategically optimize your upstream and downstream processes and decrease the timeline from optimization to commercial manufacturing.

This digital event features industry experts who will share best practices for streamlining processes between sponsors and CDMOs. Register today for free and you can walk away with actionable insights into aligning analytical methods and quality standards to accelerate small molecule production and reduce risk across the development lifecycle.

From plasmid design to vial-ready product, our proprietary AAVion® platform streamlines every step to accelerate your AAV program toward clinical success.

Gain direct access to our extensive global network of sites, along with the benefits of seamless process optimization, scalable commercial manufacturing solutions, and secure, dependable supply chains.

Thomas Kohl, Director of Business Development, shares the company’s microbial and mammalian capabilities and their available capacity.

By partnering with us, you gain access to our unique, interconnected network, purpose-built to overcome the breakpoints common in traditional manufacturing models.

Leveraging deep ADC expertise and experience, successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing.

Discover expert aseptic manufacturing with flexible batch sizes, regulatory excellence, and end-to-end support, specializing in sterile injectable solutions for clinical and commercial needs.